{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:17:34Z","timestamp":1775636254049,"version":"3.50.1"},"reference-count":14,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T00:00:00Z","timestamp":1114128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T00:00:00Z","timestamp":1114128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<i>Background\/Aims:<\/i> To determine whether bezafibrates have adverse effects on renal function. <i>Methods:<\/i> (1) A 3-year retrospective survey of 526 patients who were on bezafibrate for a while and 614 controls following fluctuations of serum creatinine levels. (2) A prospective study on 33 patients with previous evidence of bezafibrate-induced elevation in serum creatinine. The patients were examined after 3 months on bezafibrate 400 mg\/day and then after 3 months without bezafibrate. Eight patients repeated the tests after 3 months on bezafibrate 200 mg\/day. <i>Results:<\/i><i>Retrospective<\/i>: 295 bezafibrate-treated patients (56%) and 67 controls (11%) demonstrated fluctuations \u22670.2 mg\/dl in serum creatinine levels (p < 0.001); 113 patients (21%) and 16 controls (3%) showed fluctuations \u22670.3 mg\/dl (p < 0.001). <i>Prospective:<\/i> bezafibrate 400 mg\/dl increased serum creatinine from 1.16 \u00b1 0.19 to 1.42 \u00b1 0.2 mg\/dl (p < 0.001) and urea from 37 \u00b1 8 to 44 \u00b1 8 mg\/dl (p < 0.001); creatinine clearance (C<sub>cr<\/sub>) decreased from 104 \u00b1 23 to 82 \u00b1 27 ml\/min (p < 0.001). CPK increased from 82 \u00b1 32 to 130 \u00b158 mg\/dl (p < 0.0001) and urinary myoglobin increased from 95.4 \u00b1 21 to 199 \u00b1 99 mg\/dl (p < 0.0001). The 8 patients given bezafibrate 200 mg\/dl experienced similar dose-dependent changes. <i>Conclusions:<\/i> Bezafibrate causes quiet common, dose-dependent and reversible changes in serum creatinine in patients with normal renal function, associated with a significant increase in serum CPK and urine myoglobin, suggestive of drug-induced mild subclinical skeletal muscle injury compromising renal function.<\/jats:p>","DOI":"10.1159\/000085291","type":"journal-article","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T06:35:19Z","timestamp":1114151719000},"page":"c120-c125","source":"Crossref","is-referenced-by-count":9,"title":["Bezafibrates Cause Moderate, Reversible Impairment in Renal Function in Patients without Prior Renal Disease"],"prefix":"10.1159","volume":"100","author":[{"given":"Gideon","family":"Charach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itamar","family":"Grosskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heschi H.","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Kitzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.85.6.2089"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9149%2898%2900031-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0195-668X%2802%2900811-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2896%2991343-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1185%2F030079902125000516"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2F0140-6736%2893%2990625-Q"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007%2FBF01740664"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9149%2898%2900040-X"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2899%2902153-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1592%2Fphco.21.13.1145.34623"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9149%2892%2990463-9"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2F15.12.1993"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.151.9.1873"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000020651"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:50:09Z","timestamp":1745466609000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000085291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,22]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000085291","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"value":"1660-2110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,22]]}}}